Antisense Receives Approval to Conduct Phase IIb Trial of ATL1102 and Appoints New CEO

May 23, 2023

On May 23, 2023, Antisense Therapeutics announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy in Bulgaria. They also announced the appointment of their new CEO, Dr. James Garner, MBBS, MBA.

To read their ATL1102 trial press release, please click here.

To read their press release announcing the appointment of their CEO, please click here.

Accessible Vehicle Fund Applications Open